Following a week-long bidding war with Novo Nordisk, Pfizer has acquired obesity drug specialists Metsera for $10 billion, thanks to an intervention by the US Federal Trade Commission (FTC).  Metsera's Board of Directors unanimously recommended that Metsera stockholders approve the adoption of the amended Pfizer merger agreement and approve the merger with Pfizer.  Pfizer will […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!